Abnormal fatty acid metabolism is a core component of spinal muscular atrophy

Marc Olivier Deguise, Giovanni Baranello, Chiara Mastella, Ariane Beauvais, Jean Michaud, Alessandro Leone, Ramona De Amicis, Alberto Battezzati, Christopher Dunham, Kathryn Selby, Jodi Warman Chardon, Hugh J. McMillan, Yu Ting Huang, Natalie L. Courtney, Alannah J. Mole, Sabrina Kubinski, Peter Claus, Lyndsay M. Murray, Melissa Bowerman, Thomas H. GillingwaterSimona Bertoli, Simon H. Parson, Rashmi Kothary

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra-neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease. Methods: We analyzed clinical data collected from a large cohort of pediatric SMA type I–III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA. Results: We identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/- mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non-alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation. Interpretation: This work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.

Original languageEnglish
Pages (from-to)1519-1532
Number of pages14
JournalAnnals of Clinical and Translational Neurology
Volume6
Issue number8
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Spinal Muscular Atrophy
Fatty Acids
Dyslipidemias
Spinal Muscular Atrophies of Childhood
Motor Neuron Disease
Liver
Denervation
Fatty Liver
Lipid Metabolism
Paralysis
Histology
Triglycerides
Guidelines
Pediatrics
Phenotype
Lipids

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology

Cite this

Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. / Deguise, Marc Olivier; Baranello, Giovanni; Mastella, Chiara; Beauvais, Ariane; Michaud, Jean; Leone, Alessandro; De Amicis, Ramona; Battezzati, Alberto; Dunham, Christopher; Selby, Kathryn; Warman Chardon, Jodi; McMillan, Hugh J.; Huang, Yu Ting; Courtney, Natalie L.; Mole, Alannah J.; Kubinski, Sabrina; Claus, Peter; Murray, Lyndsay M.; Bowerman, Melissa; Gillingwater, Thomas H.; Bertoli, Simona; Parson, Simon H.; Kothary, Rashmi.

In: Annals of Clinical and Translational Neurology, Vol. 6, No. 8, 01.01.2019, p. 1519-1532.

Research output: Contribution to journalArticle

Deguise, MO, Baranello, G, Mastella, C, Beauvais, A, Michaud, J, Leone, A, De Amicis, R, Battezzati, A, Dunham, C, Selby, K, Warman Chardon, J, McMillan, HJ, Huang, YT, Courtney, NL, Mole, AJ, Kubinski, S, Claus, P, Murray, LM, Bowerman, M, Gillingwater, TH, Bertoli, S, Parson, SH & Kothary, R 2019, 'Abnormal fatty acid metabolism is a core component of spinal muscular atrophy', Annals of Clinical and Translational Neurology, vol. 6, no. 8, pp. 1519-1532. https://doi.org/10.1002/acn3.50855
Deguise, Marc Olivier ; Baranello, Giovanni ; Mastella, Chiara ; Beauvais, Ariane ; Michaud, Jean ; Leone, Alessandro ; De Amicis, Ramona ; Battezzati, Alberto ; Dunham, Christopher ; Selby, Kathryn ; Warman Chardon, Jodi ; McMillan, Hugh J. ; Huang, Yu Ting ; Courtney, Natalie L. ; Mole, Alannah J. ; Kubinski, Sabrina ; Claus, Peter ; Murray, Lyndsay M. ; Bowerman, Melissa ; Gillingwater, Thomas H. ; Bertoli, Simona ; Parson, Simon H. ; Kothary, Rashmi. / Abnormal fatty acid metabolism is a core component of spinal muscular atrophy. In: Annals of Clinical and Translational Neurology. 2019 ; Vol. 6, No. 8. pp. 1519-1532.
@article{2f461284ee0242f18c05bd03d84fc7ff,
title = "Abnormal fatty acid metabolism is a core component of spinal muscular atrophy",
abstract = "Objective: Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra-neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease. Methods: We analyzed clinical data collected from a large cohort of pediatric SMA type I–III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA. Results: We identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/- mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non-alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation. Interpretation: This work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.",
author = "Deguise, {Marc Olivier} and Giovanni Baranello and Chiara Mastella and Ariane Beauvais and Jean Michaud and Alessandro Leone and {De Amicis}, Ramona and Alberto Battezzati and Christopher Dunham and Kathryn Selby and {Warman Chardon}, Jodi and McMillan, {Hugh J.} and Huang, {Yu Ting} and Courtney, {Natalie L.} and Mole, {Alannah J.} and Sabrina Kubinski and Peter Claus and Murray, {Lyndsay M.} and Melissa Bowerman and Gillingwater, {Thomas H.} and Simona Bertoli and Parson, {Simon H.} and Rashmi Kothary",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/acn3.50855",
language = "English",
volume = "6",
pages = "1519--1532",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Abnormal fatty acid metabolism is a core component of spinal muscular atrophy

AU - Deguise, Marc Olivier

AU - Baranello, Giovanni

AU - Mastella, Chiara

AU - Beauvais, Ariane

AU - Michaud, Jean

AU - Leone, Alessandro

AU - De Amicis, Ramona

AU - Battezzati, Alberto

AU - Dunham, Christopher

AU - Selby, Kathryn

AU - Warman Chardon, Jodi

AU - McMillan, Hugh J.

AU - Huang, Yu Ting

AU - Courtney, Natalie L.

AU - Mole, Alannah J.

AU - Kubinski, Sabrina

AU - Claus, Peter

AU - Murray, Lyndsay M.

AU - Bowerman, Melissa

AU - Gillingwater, Thomas H.

AU - Bertoli, Simona

AU - Parson, Simon H.

AU - Kothary, Rashmi

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra-neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease. Methods: We analyzed clinical data collected from a large cohort of pediatric SMA type I–III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA. Results: We identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/- mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non-alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation. Interpretation: This work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.

AB - Objective: Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder leading to paralysis and subsequent death in young children. Initially considered a motor neuron disease, extra-neuronal involvement is increasingly recognized. The primary goal of this study was to investigate alterations in lipid metabolism in SMA patients and mouse models of the disease. Methods: We analyzed clinical data collected from a large cohort of pediatric SMA type I–III patients as well as SMA type I liver necropsy data. In parallel, we performed histology, lipid analysis, and transcript profiling in mouse models of SMA. Results: We identify an increased susceptibility to developing dyslipidemia in a cohort of 72 SMA patients and liver steatosis in pathological samples. Similarly, fatty acid metabolic abnormalities were present in all SMA mouse models studied. Specifically, Smn2B/- mice displayed elevated hepatic triglycerides and dyslipidemia, resembling non-alcoholic fatty liver disease (NAFLD). Interestingly, this phenotype appeared prior to denervation. Interpretation: This work highlights metabolic abnormalities as an important feature of SMA, suggesting implementation of nutritional and screening guidelines in patients, as such defects are likely to increase metabolic distress and cardiovascular risk. This study emphasizes the need for a systemic therapeutic approach to ensure maximal benefits for all SMA patients throughout their life.

UR - http://www.scopus.com/inward/record.url?scp=85070657590&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070657590&partnerID=8YFLogxK

U2 - 10.1002/acn3.50855

DO - 10.1002/acn3.50855

M3 - Article

AN - SCOPUS:85070657590

VL - 6

SP - 1519

EP - 1532

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

SN - 2328-9503

IS - 8

ER -